On February 20, 2020 Interim Reported that result of Q4 2019 (Press release, Oncopeptides, FEB 20, 2020, View Source [SID1234554537]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Financial overview October 1 – December 31, 2019
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 244,9 M (loss: 112.0)
Loss per share, before and after dilution, was SEK 4.42 (loss: 2.54)
On December 31 cash and cash equivalents amounted to SEK 926.2 M (375.6)
Significant events during the period October 1 – December 31, 2019
In early December, an advisory meeting was held with the FDA is preparing for Oncopeptides’application for accelerated market approval
At the annual American Hematology Meeting (ASH) (Free ASH Whitepaper) in December, Oncopeptides presented updated efficacy and safety data from the pivotal phase 2 study HORIZON in RRMMnpatients and promising data from the phase 2 combination study ANCHOR
At the ASH (Free ASH Whitepaper) meeting it was also presented preclinical data regarding melflufen for AL amyloidosis, which forms the basis for the clinical program where the patient recruitment has started
In the process of preparing for a potential launch in the United States, Joseph Horvat was appointed as President North America
At an Extraordinary General Meeting in December, it was resolved to issue warrants and to extend the board’s authorization to issue shares
Financial overview of the group
SEK thousand 2019
Oct – Dec 20181)
Oct – Dec 2019
Jan – Dec 20181)
Jan – Dec
Net sales – – – –
Operating loss -244,244 -111,859 -739,392 -410,963
Loss before tax -244,400 -111,861 -739,392 -410,965
Loss for the period -244,904 -112,008 -740,705 -411,112
Earnings per share before and
after dilution (SEK) -4.42 -2.54 -14.33 -9.58
Cash flow from operating activities -216,974 -108,855 -690,566 -333,727
Cash and cash equivalents
at the end of the period 926,186 375,617 926,186 375,617
Research & development costs/
Operating expenses % 64% 81% 74% 76%
1) Earlier periods have been adjusted to reflect correction of errors, see note 7.
Conference call for investors, analysts and the media
The Interim Report Q4 2019 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Thursday February 20, 2020 at 14.00 (CET).
The conference call will also be streamed via a link on the website: www.oncopeptides.com
Phone numbers for participants from:
Sweden: +46 8 505 583 56
Europe: +44 3333 009 031
USA: +1 833 526 83 82
Financial calendar
Interim Report Q1, 2020: May 26, 2020
Annual General Meeting May 26, 2020
Interim Report Q2, 2020: August 26, 2020
Interim Report Q3, 2020: November 19, 2020
For further information
Jakob Lindberg, CEO, Oncopeptides AB
E-mail: [email protected]
Telephone: +46 (0)8 615 20 40
Rein Piir, Head of Investor Relations, Oncopeptides AB
E-mail: [email protected]
Telephone: +46 (0)70 853 72 92
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 20, 2020.